Literature DB >> 21741610

Predictors of low clopidogrel adherence following percutaneous coronary intervention.

Paul Muntner1, Devin M Mann, Mark Woodward, James W Choi, Robert C Stoler, Daichi Shimbo, Michael E Farkouh, Michael C Kim.   

Abstract

Few data are available on factors associated with low adherence or early clopidogrel discontinuation after percutaneous coronary intervention (PCI). Patients (n = 284) were evaluated before hospital discharge after PCI to identify factors associated with low adherence to clopidogrel 30 days later. Adherence to daily medications before PCI was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8) and categorized as low (score <6), medium (score 6 to <8), or high (score 8). Low adherence to clopidogrel was defined as MMAS-8 score <6 (n = 21) or having discontinued clopidogrel (n = 11), which was ascertained during a 30-day interview after PCI. At 30 days after PCI, 11% of patients had low adherence to clopidogrel. Odds ratios (95% confidence intervals [CIs]) for low adherence to clopidogrel were 3.78 (1.09 to 13.1), 3.06 (1.36 to 6.87), 2.46 (0.97 to 6.27), and 3.36 (0.99 to 11.4) for patients who before PCI reported taking smaller doses of medication because of cost, had difficulty filling prescriptions, had difficulty reaching their primary physician, and were not comfortable asking their doctor for instructions, respectively. Odds ratios (95% CIs) for low clopidogrel adherence after PCI in patients with medium and low versus high adherence to daily medications before PCI were 6.13 (1.34 to 28.2) and 10.9 (2.46 to 48.7), respectively. The c-statistic associated with MMAS-8 scores before PCI for discriminating low clopidogrel adherence at 30 days after PCI was 0.733 (95% CI 0.650 to 0.852). In conclusion, adherence to daily medications before PCI may be a useful indicator for identifying patients who will have low clopidogrel adherence after PCI.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741610      PMCID: PMC3586559          DOI: 10.1016/j.amjcard.2011.04.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

2.  2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee.

Authors:  Spencer B King; Sidney C Smith; John W Hirshfeld; Alice K Jacobs; Douglass A Morrison; David O Williams; Ted E Feldman; Morton J Kern; William W O'Neill; Hartzell V Schaff; Patrick L Whitlow; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2007-12-13       Impact factor: 29.690

3.  Adherence to medications by patients after acute coronary syndromes.

Authors:  Anchal Sud; Eva M Kline-Rogers; Kim A Eagle; Jianming Fang; David F Armstrong; Krishna Rangarajan; Richard F Otten; Dana R Stafkey-Mailey; Stephanie D Taylor; Steven R Erickson
Journal:  Ann Pharmacother       Date:  2005-10-04       Impact factor: 3.154

4.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

5.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.

Authors:  R Horne; J Weinman
Journal:  J Psychosom Res       Date:  1999-12       Impact factor: 3.006

6.  Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.

Authors:  John A Spertus; Richard Kettelkamp; Clifton Vance; Carole Decker; Philip G Jones; John S Rumsfeld; John C Messenger; Sanjaya Khanal; Eric D Peterson; Richard G Bach; Harlan M Krumholz; David J Cohen
Journal:  Circulation       Date:  2006-06-12       Impact factor: 29.690

7.  Secondary prevention of coronary heart disease: patient beliefs and health-related behaviour.

Authors:  Molly Byrne; Jane Walsh; Andrew W Murphy
Journal:  J Psychosom Res       Date:  2005-05       Impact factor: 3.006

8.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

9.  New medication adherence scale versus pharmacy fill rates in seniors with hypertension.

Authors:  Marie Krousel-Wood; Tareq Islam; Larry S Webber; Richard N Re; Donald E Morisky; Paul Muntner
Journal:  Am J Manag Care       Date:  2009-01       Impact factor: 2.229

10.  Predictive validity of a medication adherence measure in an outpatient setting.

Authors:  Donald E Morisky; Alfonso Ang; Marie Krousel-Wood; Harry J Ward
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-05       Impact factor: 2.885

View more
  7 in total

1.  Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence.

Authors:  Marya J Cohen; Shimon Shaykevich; Courtney Cawthon; Sunil Kripalani; Michael K Paasche-Orlow; Jeffrey L Schnipper
Journal:  J Hosp Med       Date:  2012-04-02       Impact factor: 2.960

2.  Association of Medicare Part D low-income cost subsidy program enrollment with increased fill adherence to clopidogrel after coronary stent placement.

Authors:  O Kenrik Duru; Sarah Edgington; Carol Mangione; Norman Turk; Chi-Hong Tseng; Lindsay Kimbro; Susan Ettner
Journal:  Pharmacotherapy       Date:  2014-10-14       Impact factor: 4.705

3.  Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up.

Authors:  Jinshuang Li; Yuansheng Fan; Tiantian Zhu; Jun Chen; Deyu Kong; Haoyu Meng; Jing Zhang; Ke Xu; Sen Ye; Yuqin Ji; Chunjian Li
Journal:  Eur J Clin Pharmacol       Date:  2018-08-20       Impact factor: 2.953

4.  The need of a multicomponent guiding approach to personalize clopidogrel treatment.

Authors:  Conti Valeria; Sellitto Carmine; Manzo Valentina; Iannaccone Teresa; Costantino Maria; Torsiello Martina; Accarino Giancarlo; Nicolella Giovanna; Corbi Graziamaria; Filippelli Amelia
Journal:  Pharmacogenomics J       Date:  2020-10-09       Impact factor: 3.550

5.  Systematic reviews: causes of non-adherence to P2Y12 inhibitors in acute coronary syndromes and response to intervention.

Authors:  Nina Johnston; John Weinman; Lucy Ashworth; Peter Smethurst; Jad El Khoury; Clare Moloney
Journal:  Open Heart       Date:  2016-10-19

6.  Effect of acute coronary syndrome patients' education on adherence to dual antiplatelet therapy.

Authors:  Hassan El-Toukhy; Abdullah Omar; Manal Abou Samra
Journal:  J Saudi Heart Assoc       Date:  2017-03-08

7.  Adherence to prophylactic dual antiplatelet therapy in patients with acute coronary syndrome - A study conducted at a Saudi university hospital.

Authors:  Ziyad Alrabiah; Syed Wajid; Ibrahim Alsulaihim; Sultan Alghadeer; Abdulaziz Alhossan; Salmeen D Babelghaith; Mohamed Al-Arifi
Journal:  Saudi Pharm J       Date:  2020-02-03       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.